Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Thierry André

49PUBLICATIONS
207CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

Sort by Publication Date:
|Apr 14, 2026
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

Benoist Chibaudel, Louis-Marie Dourthe, Thierry André

|Mar 26, 2026
Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Andrea Marques, Julie Henriques, Dewi Vernerey

|Jan 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

John H Strickler, Andrea Cercek, Salvatore Siena

|Dec 29, 2025
Organ-sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision-making.

Martin Duval, Antoine Dardenne, Thomas Samaille

|Nov 14, 2025
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Mohamed E Salem, Alberto Puccini, Elizabeth Mauer

|Oct 06, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Ming Lei, Michael J Overman, Jin Yao

Pageof 9

Frequent Collaborators

21 joint publications

Romain Cohen

14 joint publications

Julien Taieb

13 joint publications

Qian Shi

11 joint publications

Sara Lonardi

9 joint publications

Takayuki Yoshino

8 joint publications

Josep Tabernero

8 joint publications

Aimery De Gramont

8 joint publications

Richard R M Goldberg

6 joint publications

Eric Van Cutsem

5 joint publications

Thomas J George

Frequent Collaborators

21 joint publications

Romain Cohen

14 joint publications

Julien Taieb

13 joint publications

Qian Shi

11 joint publications

Sara Lonardi

Top Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on : Aug 19, 2025

1.5K
Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
12:37

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on : Sep 11, 2012

48.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

7.6K
See more related videos

Top Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on : Aug 19, 2025

1.5K
Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
12:37

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on : Sep 11, 2012

48.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on : Dec 11, 2017

7.6K
See more related videos